Clinical Stage Pharma

Developing small molecules for the treatment of gastric acid related diseases.

About Cinclus Pharma
Cinclus Pharma

The Next Leap Forward

Blockbuster Proton Pump Inhibitors (PPIs) such as Losec and Nexium have not been able to provide all gastroesophageal reflux disease (GERD) patients with sufficient disease control. The time has now come for Potassium-Competitive Acid Blockers (P-CABs) to take the next leap forward in the treatment of acid-related diseases. Cinclus Pharma’s clinical stage drug candidate linaprazan glurate takes a new approach to provide improved management of GERD and for the treatment of Helicobacter Pylori (H.Pylori) infection.

Learn more

Cinclus Pharma man with GERD startpage

Latest pressreleases

cinclus pharma illustration of linazapran molecule grey
Our lead asset

Linaprazan glurate

Built on world-leading industrial tradition, linaprazan glurate is a gastric acid blocker and therapy with great potential for healing GERD. Several clinical Phase I trials have been successfully completed and in 2022 the clinical Phase II trial was completed. Linaprazan glurate represents an improved mode of action with the potential for superior clinical efficacy and beneficial pharmacokinetic profile compared to PPIs.

Learn more

Latest News

Christer Börsdagen ENG

Cinclus Pharma participates at Avanza's Börsdag

Cinclus Pharma's CEO Christer Ahlberg, will talk about the company's latest updates and the development of linaprazan glurate at Avanza's Börsdag on May 22nd.

Cinclus Pharma Webbnyhet 2540X1200

Cinclus Pharma at Redeye Investor Forum 2024

Christer Ahlberg, CEO of Cinclus Pharma, was invited to present the company's latest updates and the development of linaprazan glurate at the Redeye Investor Forum in Gothenburg on April 18, 2024.

Cinclus News Image Christer Trill 01 (1)

Cinclus Pharma presented at ABGSC investor days

Cinclus Pharma's CEO, Christer Ahlberg, presented Cinclus Pharma at the ABGCS seminar on November 22-23.

cinclus pharma bistro with greenery in the ceiling
Reflux diseases


Most people can relate to discomfort from heartburn and regurgitation, two of the most common symptoms caused by GERD. Symptoms often occur during or after eating and drinking, which affects both motivation and the ability to enjoy social activities such as picnics, dinners, events, or just a cup of coffee with friends. More severe stages of GERD with the presence of esophageal erosions (eGERD) or ulcerations (complicated GERD) can be very painful.

Learn more about GERD

"Cinclus Pharma wants to accomplish a paradigm shift in the treatment of acid-related diseases. We will do this by registering and launching our effective P-CAB linaprazan glurate and making it available worldwide."